Epilepsy is one of the leading causes of chronic neurological morbidity worldwide. Acquired epilepsy may result from a number of conditions, such as brain injury, anoxia, tumors, stroke, neurotoxicity, and prolonged seizures. Sex differences have been observed in many seizure types; however, some sex-specific seizure disorders are much more prevalent in women. Despite some inconsistencies, substantial data indicates that sensitivity to seizure stimuli differs between the sexes. Men generally exhibit greater seizure susceptibility than women, whereas many women with epilepsy experience a cyclical occurrence of seizures that tends to center around the menstrual period, which has been termed catamenial epilepsy. Some epilepsy syndromes show gender differences with female predominance or male predominance. Steroid hormones, endogenous neurosteroids, and sexually dimorphic neural networks appear to play a key role in sex differences in seizure susceptibility. Neurosteroids, such as allopregnanolone, reflect sex differences in their anticonvulsant activity. This Review provides a brief overview of the evidence for sex differences in epilepsy and how sex differences influence the use of neurosteroids in epilepsy and epileptogenesis. V C 2016 Wiley Periodicals, Inc.
Epilepsy is one of the leading causes of chronic neurological morbidity worldwide. Unlike stroke, migraine, and other neurological diseases, epilepsy diagnosis is associated with a certain degree of stigma, with patients experiencing restrictions related to driving, swimming, and certain jobs. According to the newly proposed classification of epilepsy, epilepsy of unknown etiology (primary epilepsy; 50%) is characterized by generalized seizures with no apparent cause. Epilepsy resulting from structural/metabolic etiologies (acquired epilepsy; 50%) may result from a number of circumstances, including neurotoxicity, brain injury, anoxia, metabolic imbalances, stroke, status epilepticus (SE), prolonged seizures attributable to drug withdrawal, tumors, or encephalitis (Berg et al., 2010) . Sex differences have been observed in many types of seizures (Park et al., 2008; Reddy, 2014) ; however, there are sex-specific seizure disorders that are much more prevalent in women. Neurosteroids have promising potential for the treatment of brain disorders (Reddy and Estes, 2016) . This Review provides a brief overview of the evidence for sex differences in epilepsy and how sex differences influence the use of neurosteroids in epilepsy and epileptogenesis.
SEX DIFFERENCES IN EPILEPSY AND
SEIZURE SUSCEPTIBILITY Epilepsy is a chronic neurological disorder characterized by the unpredictable occurrence of seizures.
Epilepsy affects an estimated 3 million Americans and about 65 million people worldwide in a variety of ways (Jacobs et al., 2009; Hesdorffer and Begley, 2013) . Approximately 150,000 new cases of epilepsy are diagnosed in the United States annually (Hesdorffer and Begley, 2013) . Epileptic seizures are classified into focal and generalized seizures. Focal seizures begin focally and account for approximately 60% of all epilepsies, whereas generalized seizures involve both hemispheres and account for the remaining 40% of epilepsy types (Duncan et al., 2006; Berg et al., 2010; Reddy, 2014) . Epilepsy can develop as a result of an abnormality in the connectivity of neural networks, an imbalance in inhibitory and excitatory neurotransmitters, or a combination of these conditions. Epileptogenesis is the process by which a brain becomes progressively epileptic because of an initial precipitating event, such as brain injury, stroke, infection, or prolonged seizures. Epileptogenesis includes three distinct stages, the initial precipitating event, the latent period, and the chronic period with spontaneous seizures. Neuroinflammation and neurodegeneration appear to trigger epileptogenesis; however, other factors play critical roles in the neuropathology (Pitk€ anen et al., 2009; Reddy, 2013b) .
The incidence of epilepsy is sex specific, with men exhibiting relatively greater seizure susceptibility than women (Verotti et al., 2007; Herzog et al., 2004; Herzog, 2009; Reddy, 2009b,a) . Although epilepsy affects more men than women, women exhibit seizure syndromes that are much more complex and often intractable. Epilepsy affects an estimated 25 million women worldwide. There are about 1.2 million women of childbearing age with epilepsy in the United States (El-Sayed, 1998; Kaplan et al., 2007; Harden et al., 2009) . Epilepsy is associated with special concerns for women of childbearing age (Morrell, 2003) . There is abundant evidence of hormonal effects on seizures; many women report that their seizure patterns change at puberty, menstrual cycle, and menopause. The natural fluctuation in steroid hormones that occurs during the menstrual cycle significantly influences seizure patterns and potentially influences drug therapy. An estimated 10 million women in the United States and 100 million women worldwide use hormonal contraceptives. This is associated with some risks, including drug interactions and seizure exacerbations (Reddy, 2010b; Younus and Reddy, 2016) . However, there is little evidence for major gender-related differences in efficacy of antiepileptic drugs (E. Perucca et al., 2014) . Gender issues in epilepsy therapy are related mainly to pharmacokinetics and the impact of sexspecific physiological factors such as pregnancy, menstrual cycle, and drug interactions.
There is a growing interest in sex differences in many neurological disorders. Sex difference in seizure susceptibility is one of the re-emerging issues of epilepsy. Clinical evidence shows gender-and age-related expression in many seizure syndromes. Many studies have shown that the overall incidence of epilepsy is generally higher in males than in females (Lavados et al., 1992; Hauser et al., 1993; Hauser, 1997; TekleHaimanot et al., 1997; Christensen et al., 2005 Christensen et al., , 2007 Christensen et al., , 2009 Benn et al., 2008) . Despite some inconsistences in the reports, considerable data indicates that men exhibit greater seizure susceptibility than females, whereas females tend to have greater fluctuation in their susceptibility to seizures, including menstrual cycle-related influences and changes in seizure activity (Joensen, 1986; Kotsopoulos et al., 2002; P. Perucca et al., 2014) . Many epilepsy syndromes show gender predominance Engel, 1998, 2014) . Female predominance is found in juvenile myoclonic epilepsy, childhood absence epilepsy, and photosensitive epilepsy, whereas male predominance is reportedly more common in West's syndrome, Dravet's syndrome, Landau-Kleffner's syndrome, and myoclonic atonic seizures. With the previous classification scheme, idiopathic generalized epilepsy and cryptogenic localization-related epilepsies (currently classified as unknown etiology) are more frequently diagnosed in women, but localization-related symptomatic epilepsies (currently classified as focal epilepsies because of structural metabolic etiologies) are diagnosed more frequently in men (Hauser, 1997; Christensen et al., 2005) . The seizure remission outcomes are similar between men and women; however, the risk of sudden unexpected death in epilepsy is greater in men (Hesdorffer et al., 2011) . Some forms of epilepsy affect only women. These conditions are mostly genetically determined or based on natural fluctuations in hormonal status. For example, PCDH19 pediatric epilepsy is a rare genetic epileptic syndrome that affects females (Tan et al., 2015; Ikeda et al., 2016) . Limited statistical power because of a small subject cohort is one major limitation in most studies of sex differences.
The mechanisms underlying sex differences in epilepsy are unknown. Differences in seizure susceptibility between men and women may arise from a myriad of factors, including microsomal enzyme activity, steroid hormones, and sexual dimorphisms in the neuronal networks of the brain. Sex-related differences in neurosteroids, neuroendocrine control, steroid hormones, and other molecular signaling in inhibitory neurotransmission in the brain could influence seizure sensitivity in males and females (Herzog, 2007; Verotti et al., 2007; Chudomel et al., 2009; Reddy, 2009b; Herzog et al., 2012; Tabatadze et al., 2015) .
ROLE OF NEUROSTEROIDS IN SEX-SPECIFIC CATAMENIAL EPILEPSY
For many women with epilepsy, susceptibility to seizures conforms to their menstrual cycle. This sex-specific neuroendocrine disorder is referred to as catamenial epilepsy and affects up to 70% of women with epilepsy. Three types of catamenial seizures have been defined, perimenstrual, periovulatory, and inadequate luteal phase (Herzog et al., 1997) . The most commonly diagnosed type of catamenial epilepsy is perimenstrual catamenial epilepsy, in which women experience a sharp increase in seizure activity before, during, or after the onset of menstruation (Bazan et al., 2005; Reddy, 2009a) . These types of catamenial epilepsy have been described in detail in previous articles (Reddy, 2013a; Reddy, 2014) . There is no clear evidence of genetic components; therefore, catamenial epilepsy has been categorized an as acquired disorder (Herzog et al., 2004; Herzog, 2007; Quigg et al., 2009) . For this reason, several mechanisms have been proposed as possible causes of catamenial epilepsy, including an imbalance of estradiol. It has been known for many years that estradiol plays a key role in the exacerbation of seizures in women (Logothetis et al., 1959; B€ ackstr€ om, 1976; Jacono and Robinson, 1987; Tauboll et al., 2015) , and it has been shown that plasma levels of estradiol increase during both the follicular and the luteal phases of the normal menstrual cycle. Thus, an increase or disruption in the estrogen-to-progesterone ratio during the perimenstrual period might at least partially contribute to the development of perimenstrual seizure exacerbation (Bonuccelli et al., 1989; Herzog et al., 1997) .
Progesterone also plays an important role in catamenial epilepsy and has long been known to have antiseizure, anticonvulsant, and antiepileptic characteristics in a variety of animal models of epilepsy (Craig, 1966; Landgren et al., 1978; Reddy, 2009a; . The antiseizure mechanisms of progesterone are mediated mostly by its metabolic conversion into neurosteroids (Reddy et al., 2001a (Reddy et al., ,b, 2010a Reddy and Mohan, 2011; Reddy and Ramanathan, 2012) . Natural variations in progesterone levels occur during the menstrual cycle and can influence catamenial seizure susceptibility (El-Khayat et al., 2008; Tuveri et al., 2008) . In this light, seizures tend to increase when there is a decrease in the serum progesterone-to-estrogen ratio during the premenstrual phase of the cycle, and seizures start to decrease during the midluteal phase while progesterone levels are high (B€ ackstr€ om, 1976; Bonucelli et al., 1989; Herzog et al., 2001) . Recent clinical trials have indicated that administration of progesterone reduces seizures in women with epilepsy (B€ ackstr€ om et al., 1984; Herzog, 2009) . These emerging data indicate that catamenial seizures are linked to a rapid decline in progesterone levels at about the time of menstruation.
Neurosteroids can play a critical role in catamenial seizure exacerbation and susceptibility in women with epilepsy. Many neurosteroids are synthesized in the brain; the most extensively studied are allopregnanolone (AP), allotetrahydro-deoxycorticosterone, and androstanediol (Reddy, 2010a) . AP and other structurally related neurosteroids act as positive allosteric modulators and direct activators of GABA A receptors. AP and related neurosteroids rapidly alter neuronal excitability and therefore act as powerful anticonvulsants (Harrison et al., 1987; Hosie et al., 2007; Reddy, 2010a; Reddy and Jian, 2010; Carver and Reddy, 2013; van Luijtelaar et al., 2014) . When neurosteroid levels fluctuate, control of seizures can be lost. It has been suggested that the withdrawal of progesteronederived neurosteroids can lead to an increase in neuronal excitability, predisposing one to seizures (Reddy et al., 2007 Reddy, 2013b) . Additionally, the plasticity in the GABA A receptor subunits could also be associated with enhanced seizure susceptibility in perimenstrual catamenial epilepsy, as seen in animal studies (Smith et al., 2007; Gangisetty and Reddy, 2010; Wu et al., 2013) . These neuroendocrine changes can result in reduced inhibition, resulting in enhanced excitability, which, among other effects, predisposes one to seizures.
Based on neurosteroid physiology, Reddy and colleagues have developed multiple rodent models of catamenial epilepsy that are described in detail in earlier publications (Reddy et al., 2007 Reddy and Zeng, 2007) . Withdrawal of neurosteroids leads to a decreased seizure threshold and an increase in seizures (Reddy et al., 2007 Reddy and Zeng, 2007) , suggesting that endogenous neurosteroids play a critical role in catamenial seizures. These models were used as tools to investigate novel drug therapies for catamenial epilepsy (Reddy and Rogawski, 2000a ,b, 2001 , 2009 . The outcomes of these preclinical studies have led to the proposal for a "neurosteroid replacement" therapy (Reddy and Rogawski, 2009) . With this treatment, a neurosteroid could be administered in a "pulse" prior to menstruation, and then either withdrawn or continuously administered at lower doses throughout the month. Low doses of neurosteroid are expected to contribute little to the anticonvulsant activity during the majority of the menstrual cycle but may be critical in preventing the occurrence of perimenstrual catamenial seizures .
SEX DIFFERENCES IN NEUROSTEROID
ACTIONS Emerging experimental data suggests that gender may affect sensitivity to neurosteroids (Reddy et al., 2004; GorinMeyer et al., 2007; Reddy, 2009b) . Endocrine fluctuations of progesterone and other steroids in plasma levels can influence and mediate the availability of neurosteroids. For this reason, differences are found in the concentration of neurosteroids in the brain between males and females. Furthermore, brain development also differs between genders and influences the function of neurosteroids (Reddy, 2009b) . Although neurosteroids are capable of regulating inhibition and produce behavioral effects in both genders, regulation of neurosteroid activity may be sex specific (Gulinello and Smith, 2003) . Differences in maximal GABA A receptor potentiation have been observed between male and female rats for tetrahydrodeoxycorticosterone (THDOC) but not for allopregnanolone or androgenic neurosteroids (Wilson and Biscardi, 1997) .
Sex Differences in Antiseizure Activity of Progesterone and Allopregnanolone
Progesterone is an anticonvulsant hormone. Many studies have shown that GABA A receptor-modulating neurosteroids, which are synthesized from progesterone, mediate protective effects in the brain (Kokate et al., 1999; Reddy et al., 2004) . However, the potential sex differences in the anticonvulsant activity or progesterone have not been widely studied. We tested the ability of progesterone and neurosteroids to protect against pentylenetetrazol (PTZ)-induced seizures in male and female mice (Reddy et al., 2004) . Progesterone protected both male and female mice against PTZ-induced seizures in a dose-dependent fashion. However, in female mice, the dose-response curve for antiseizure activity of progesterone was significantly shifted in a parallel fashion to the left of that of male mice, indicating an increase in the antiseizure potency of progesterone in female mice. Because the antiseizure activity of progesterone is due mainly to its metabolic conversion to the neurosteroid allopregnanolone, we also evaluated allopregnanolone for protective activity in male and female mice in the PTZ test. Just as progesterone did, allopregnanolone protected mice in a dose-dependent fashion (Reddy et al., 2004) . The doseresponse curve for the neurosteroid in male animals was shifted to the right of that for females, indicating reduced potency in the males relative to females. Using progesterone receptor (PR) knockout mice, we further confirmed that such gender-related differences in the antiseizure potency of progesterone or allopregnanolone are unlikely to be due to differences in PRs in the brain (Reddy et al., 2004) .
These findings are in line with previous reports suggesting that female animals are more sensitive to the CNS actions of progesterone than males (Holmes and Weber, 1984; Finn and Gee, 1994; Mohammad et al., 1998; Reddy and Kulkarni, 1999) . The gender-related difference in progesterone protection is not due to known differences in the density or distribution of the PR in female and male brains . However, the role of sexual dimorphism or brain region involved remains unclear. It is possible, however, that endocrine differences between females and males are responsible. It has been established that testosterone and related androgens decrease AP's antiseizure protection (Edwards et al., 2001; Reddy, 2008) , which sheds light on the phenomenon of reduced potency of progesterone in males. Alternative explanations include gender differences in the bioavailability or pharmacokinetics of progesterone and allopregnanolone or differences in the sensitivity of GABA A receptors to these compounds.
Sex Differences in Androgenic Neurosteroids
There several androgenic neurosteroids in the brain, such as androstanediol and etiocholanone, that are derived from testosterone or other intermediate steroid hormones (Reddy, 2008) . Although steroid hormones play a key role in gender differences in susceptibility to epileptic seizures, the functional role of androgenic neurosteroids in gender differences in seizure susceptibility remains unclear. We investigated the efficacy and potency of AP and androstanediol against pilocarpine-induced status epilepticus (SE) in both male and female mice and assessed the potential pharmacokinetic factors (Reddy, 2009b) . SE was successfully induced by pilocarpine in adult male and female mice. The protective activity of the two GABAergic neurosteroids was tested in a dose-dependent fashion. Our results showed no significant differences in baseline seizure sensitivity to pilocarpine between genders (Reddy, 2009b) . Androstanediol was found to have a dosedependent protection against pilocarpine-induced SE in both male and female mice. However, female mice exhibited significantly enhanced sensitivity to the protective activity of androstanediol compared with males. Gender differences in antiseizure potency were also observed with AP (Reddy, unpublished data) . Overall, these results strongly support the emerging notion that endogenous GABAergic neurosteroids play a key role in gender differences in seizure susceptibility and that the differences in neurosteroid sensitivity between genders are not related to pharmacokinetic factors.
MOLECULAR MECHANISMS OF SEX DIFFERENCES IN ANTICONVULSANT
NEUROSTEROIDS Despite the growing reports of sex differences in the actions of neurosteroids, limited research has been conducted to investigate the underlying mechanisms in experimental models. Sex differences in the protective effects of neurosteroids may arise from variations between men and women in factors such as steroid hormones, metabolic activity, and biologic differences in neuronal receptors or neuronal networks in the brain (Finn and Gee, 1994; Li et al., 2007; Wu et al., 2013; Tabatadze et al., 2015) . This section reviews the available evidence on the sexual dimorphism in neuronal circuits and GABAergic receptor targets for neurosteroids.
Sex-Related Plasticity in Neurosteroid Target Receptors
Steroid hormones act in discrete regions of the female brain to regulate sex behavior and other aspects of reproduction through classical genomic actions mediated by steroid receptors. Steroid receptors are present in many brain regions. Thus, it is possible that differential distribution of steroid hormones could account for sex differences in seizure susceptibility. It is well known that female mice and rats are more sensitive to the central nervous system actions of progesterone than males. However, PR knockout (PRKO) female mice are also more sensitive to the anticonvulsant effects of progesterone than males (Reddy et al., 2004) , indicating that known differences in the density or distribution of the PRs in the female and male brain are not solely responsible for the sexually dimorphic effects of neurosteroids.
The ovarian cycle modulates behavior and seizure susceptibility in close association with fluctuations in neurosteroid levels (Reddy and Kulkarni, 1999; MolinaHernandez et al., 2001; Maguire et al., 2005) . Neurosteroids have influences on behavioral and excitability changes as well as on inhibition and, therefore, are linked to changes in expression of GABA A receptors. Furthermore, fluctuations in progesterone and progesterone-derived neurosteroids during the menstrual cycle have been proposed to alter GABA A receptor-mediated tonic inhibition (Maguire et al., 2005; Gangisetty and Reddy, 2010; . In a recent study, we discovered a novel role of extrasynaptic d-containing GABA A receptors as crucial mediators of the estrous cycle-related changes in neuronal excitability and seizure susceptibility in mice (Wu et al., 2013) . We showed estrous cyclerelated changes in d-containing GABA A receptor expression in different hippocampal subfields and in tonic inhibition and seizure susceptibility. These findings are highly relevant to low incidence or severity of seizures in females because extrasynaptic GABA A receptors are the main targets of neurosteroids. In addition, we sought to determine whether differences in extrasynaptic dGABA A receptor expression and function underlie the sex differences in seizure sensitivity and the anticonvulsant activity of neurosteroids. Sex differences in neurosteroid protection were unrelated to pharmacokinetic factors because concentrations of neurosteroids associated with seizure protection are similar in male and female groups. Consistent with a greater abundance of extrasynaptic dGABA A receptors in females, neurosteroids produced a greater potentiation of tonic currents in hippocampal neurons in females than in males. Therefore, it is likely that neurosteroids exhibit greater seizure protection in females because of a high abundance of extrasynaptic d subunit GABA A receptors in the hippocampus and other brain regions. However, it is likely that additional factors, including differences in phosphorylation and subunit trafficking also contribute to sex differences in the anticonvulsant potency of neurosteroids.
In addition, sexual dimorphism or distribution of steroid receptors may contribute to sex differences. Progesterone's physiological actions are mediated by the PR (Li and O'Malley, 2003) . PRs are expressed at high levels in the hypothalamus and moderate levels in the limbic areas of the brain and are also widely distributed in the hippocampus Kato et al., 1994; Alves et al., 2000; Auger and De Vries, 2002; Brinton et al., 2008) ; however, the physiological significance of these receptors remains unclear. progesterone's seizure protection is undiminished in PRKO mice and occurs mainly because of its conversion to allopregnanolone (Reddy et al., 2004) . It is likely that progesterone regulation of seizure susceptibility occurs via activation of PRs in the hippocampus. We found that animals with a targeted deletion of PRs or selective knockdowns of PR expression in the brain are less prone to epileptogenesis (Reddy and Mohan, 2011) . The persistence of this epileptic-like excitability condition was also impaired in mice lacking PRs. These data indicate that the PR pathway plays an important role in promoting epileptogenesis, long-term stability of this epileptic-like state, and modulating progesterone's ability to suppress seizures. PRs may promote epileptogenesis by influencing synaptic plasticity and tonic inhibition in the hippocampus dentate gyrus and also undergo ligand-independent activation by certain neurotransmitters (Mani and Portillo, 2010) . It has been proposed that these signaling mechanisms are involved in PR-mediated seizure susceptibility and would therefore be relevant to the pathophysiology of epilepsy in women.
Sex-Related Plasticity in Chloride Transporters
Another mechanism that has been proposed to account for sex differences in seizure sensitivity is differences in the rate of appearance of hyperpolarizing GABA A receptor signaling in female brain structures (Galanopoulou, 2008a; Giorgi et al., 2014) . During development, when intracellular chloride levels are high because of high levels of the Na-K-Cl cotransporter (NKCC1) expression and low levels of KCC2, GABA is depolarizing, and neonatal seizures are generally resistant to GABAergic drugs (Fig. 1) . Bumetanide, a blocker of NKCC1, has been shown to be a potential anticonvulsant in models of neonatal seizures. In early stages of nervous system development, GABA A receptors possess excitatory functions on neurons by chloride channel-mediated depolarization, and this switches to inhibitory function as the brain matures (Cherubini et al., 1991; Rivera et al., 1999) . Therefore, differences in the rate at which NKCC1 switches to KCC2 expression may underlie a greater susceptibility to seizures in males (Galanopoulou et al., 2001 . Developmental disparities in neurosteroid activity may be represented by the evidence that the hippocampus undergoes a longer period of this GABAdirected excitatory function in newborn males than in females (Nuñez and McCarthy, 2007; Galanopoulou, 2008a,b) . Changes in a 1 , a 3 , and d subunit expression can be influenced by fluctuations in intracellular chloride levels. These chloride concentrations can also affect tonic inhibition (Succol et al., 2012) . Steroid hormones have been shown to modify the expression of KCC2 in specific brain regions in males and females (Galanopoulou and Moshe, 2003; Galanopoulou, 2006 Galanopoulou, , 2008c . Moreover, AP and other protective neurosteroids could have differing effects in males and females experiencing potential excitotoxic or ischemic events; damage to specific neurons could alter function of chloride transporters and thereby the protective effects of benzodiazepines (Kelley et al., 2011) . Such alternations in the ratio of NKCC1 and KCC2 have been demonstrated after SE in adult animals (Sivakumaran and Maguire, 2016) . Despite such potential for contribution of chloride transporters to sex differences in seizures in younger populations, the relevance of such a mechanism in adults remains unclear.
Sexual Dimorphism in Brain Circuits
There is a good amount of published evidence for sexual dimorphism in the human brain. A detailed account of sex dimorphism in the seizure-controlling network has been published recently (Giorgi et al., 2014) . During brain development, sex hormones lead to permanent and distinct differences between males and females in various brain regions; therefore, they play key roles in producing sexual dimorphic features (Shah et al., 2012) . The presence or absence of testosterone determines the male or female brain phenotype. Furthermore, the youngest age groups have the highest prevalence of epilepsy, although males have a higher incidence of seizures than females. However, the precise mechanisms underlying the sex-dependent differentiation of the specific neuronal circuits, particularly brain regions involved in seizure control, are not clear. Sex-specific differences in the development of seizure-suppressing neuronal networks may partially account for sex-related susceptibility to seizures.
Evidence for sex differences in certain brain regions implicated in human epilepsy is increasing (see Savic and Engel, 2014) . It is likely that sex differences in cerebral morphology and structural and functional connections can contribute to gender differences in seizure susceptibility and other brain diseases. Sex differences are described primarily in the limbic and motor networks and hence might be relevant to temporal lobe epilepsy and some genetic generalized epilepsies. A detailed account of cerebral sexual dimorphism and possible implications of these differences for sex-related differences in epilepsies has been given elsewhere (Savic and Engel, 2014) .
The substantia nigra pars reticulata (SNR), a midbrain structure with a high expression of GABAergic neurons, plays a key role in seizure control in an age-and sex-dependent manner (Vel ıskov a et al., 2001 (Vel ıskov a et al., , 1996b Vel ıskov a and Moshe, 2001) . GABAergic activation of SNR at postnatal day (P) 15 has sex-specific effects on seizure control. For example, bilateral SNR microinjections of the GABA A receptor agonist muscimol have been associated with proconvulsant effects on flurothyl-induced seizures in males but not in females. Additional studies have revealed that postnatal testosterone is responsible for male proconvulsant phenotypes of SNR muscimol effects on seizures. GABAergic synaptic transmission is often excitatory early in development and then later shifts to the mature hyperpolarizing type. The adjustment occurs in females about P10 and in males about P17. This sex dimorphism may influence several other highly recognized sex differences in the development of SNR and in its regulatory role in seizures. Overall, the pathophysiological relevance of sex-related differences in extralimbic structures is still far from being clear; the dimorphism of seizure-controlling structures (e.g., SNR) appears to play a key role in sex differences in seizures and the modulating effects of GABAergic drugs.
CONCLUSIONS
In contrast clinical studies that require the inclusion of women, most experimental studies have usually been conducted with males only. In 2014, the National Institutes of Health issued a policy statement to encourage the inclusion of both males and females in all preclinical studies. This has led to a greater interest in sex differences in neurological disorders. Males are more likely to have Fig. 1 . Schematic of the mechanism of cation-chloride transporters in the brain. In neurons, KCCs control the reversal potential (E-GABA) of GABA A receptor-mediated current and voltage responses. Therefore, they influence the efficacy of GABAergic inhibition. The neuron-specific KCC isoform KCC2 is the main Cl 2 -extruding mechanism in hippocampal and neocortical principal neurons. Activation of GABA A receptors on the membranes of mature neurons generally results in the influx of Cl 2 and, subsequently, membrane hyperpolarization. However, in immature neurons, GABA is depolarizing because of the high intracellular chloride gradient (50 mM). This is attributed to an initially dominant role of Cl 2 uptake mediated by NKCC1, followed by a developmental upregulation of the Cl 2 -extruding KCC2, which renders the equilibrium potential of Cl 2 hyperpolarizing. In adult and immature neurons, the overall chloride gradient actually depends on the relative activity and abundance of NKCC1 and KCC2. Consequently, sex differences in the developmental shift from dominant NKCC1 to dominant KCC2 expression and/or activity may underlie the earlier switch of GABA A receptor signaling from depolarizing to hyperpolarizing in certain brain regions in the female brain. These changes may ultimately contribute to alteration in GABAergic inhibition and seizure susceptibility.
greater risk of epilepsy than females. The developmental susceptibility to seizures varies in females at puberty, menstrual cycle, and menopause. In experimental studies, male animals exhibit a greater susceptibility to acute seizures and epileptogenesis than females. Steroid hormones and neurosteroids are believed to play an important role in the sex-specific forms of epilepsies and gender-related seizure susceptibility-sex hormones in both males and females can influence hyperexcitability in the brain (Tauboll et al., 2015) . Menstrual and stress-related fluctuations in seizures may be related to alterations in the concentration of neurosteroids in the brain. The current and emerging data clearly support the notion that sexual dimorphism in brain structure and development contribute to differences in seizure susceptibility and sensitivity between sexes in congruence with hormonal milieu. Neurosteroids exhibit greater anticonvulsant sensitivity in females than in males. However, the potential mechanisms of sex differences in the anticonvulsant activity of neurosteroids are poorly understood. In addition to neurosteroid fluctuations, emerging evidence indicates that plasticity in GABA A receptor structure and function plays a role in seizure exacerbation in gender-specific forms of epilepsy such as catamenial epilepsy. Such neuroendocrine changes can result in reduced inhibition, resulting in enhanced excitability, which, among other effects, predisposes to catamenial seizures. Neurosteroids hold great promise for treatment of epilepsy. A better understanding of the mechanisms of sex differences in neurosteroid actions may offer improvements in treatment strategies for gender-specific forms of epilepsy.
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